General Information of Drug (ID: DMSHV9C)

Drug Name
CCX-354 Drug Info
Synonyms CCX-354-C; GSK2941266
Indication
Disease Entry ICD 11 Status REF
Autoimmune diabetes 5A10 Phase 2 [1]
Rheumatoid arthritis FA20 Phase 2 [2]
Cross-matching ID
PubChem CID
135565361
CAS Number
CAS 1010073-75-2
TTD Drug ID
DMSHV9C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-817399 DMT8L6P Rheumatoid arthritis FA20 Phase 2 [4]
AVE1701 DMJY35M Rheumatoid arthritis FA20 Phase 1 [5]
AZD4818 DM3VFKM Chronic obstructive pulmonary disease CA22 Discontinued in Phase 2 [6]
MLN3897 DMRA3EZ Rheumatoid arthritis FA20 Discontinued in Phase 2 [5]
COSALANE DMO3486 N. A. N. A. Terminated [7]
A-987306 DMU34BK Discovery agent N.A. Investigative [8]
BX 471 DM5CGXB Discovery agent N.A. Investigative [9]
Cosalane derivative DMSFXJ8 Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 1 (CCR1) TTC24WT CCR1_HUMAN Antagonist [3]

References

1 ClinicalTrials.gov (NCT01242917) A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013 Mar;72(3):337-44.
4 Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014 Sep 25;57(18):7550-64.
5 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
6 Clinical pipeline report, company report or official report of AstraZeneca (2009).
7 Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds. Bioorg Med Chem Lett. 2001 Jan 8;11(1):59-62.
8 cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
9 Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000 Jun 23;275(25):19000-8.